EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advancements and Future Directions of Dual‐Target Chimeric Antigen Receptor T‐Cell Therapy in Preclinical and Clinical Studies

Chenyun Zhang iD, Haizhou Liu iD

Journal of Immunology Research · 2025-01 · 2025 (1)

DOI: 10.1155/jimr/5845167 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Immunology Research, online erschienen am 15.01.2025. Verfasst von Chenyun Zhang und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Tsinghua, Beijing, China. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Neoplasms, T-Lymphocytes. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In recent years, chimeric antigen receptor T‐cell (CAR‐T) therapy has made groundbreaking progress in the treatment of various cancer types, particularly hematological malignancies. In the meantime, various preclinical and clinical studies have extensively explored dual‐target CAR‐T therapies which can be designed to recognize two antigens simultaneously based on the immunophenotype of tumor cells. Compared with single‐target CAR‐T approach, dual‐target CAR‐T therapies demonstrate varying degrees of superior antitumor CAR effects, prevent antigen escape and relapse, reduce on‐target off‐tumor effects, and ensure durable responses in different types of cancer. These advantages highlight the potential future prospects in this field, showing varying degrees of advancement in preclinical and clinical studies. Herein, we aimed to review different dual‐target CAR‐T studies conducted on a wide range of tumor models, summarizing the selection of target combinations, the efficacy and safety demonstrated in preclinical and clinical settings, the existing limitations, and the potential future directions of this promising therapeutic strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveReceptors, Chimeric AntigenNeoplasmsT-LymphocytesReceptors, Antigen, T-CellHumansAnimalsAntigens, NeoplasmClinical Trials as TopicTreatment Outcome

Stichwörter der Autor:innen

cancer immunotherapydual-target CAR-Thematological malignanciessolid tumors

Substanzen

Receptors, Chimeric AntigenAntigens, NeoplasmReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • School of Medicine, University of Tsinghua, Beijing, China.
  • Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

ORCID-Profile: Chenyun Zhang, Haizhou Liu

Zitieren

APA

Zhang, C., & Liu, H. (2025). Advancements and Future Directions of Dual‐Target Chimeric Antigen Receptor T‐Cell Therapy in Preclinical and Clinical Studies. Journal of Immunology Research, 2025(1). https://doi.org/10.1155/jimr/5845167

Vancouver

Zhang C, Liu H. Advancements and Future Directions of Dual‐Target Chimeric Antigen Receptor T‐Cell Therapy in Preclinical and Clinical Studies. Journal of Immunology Research. 2025;2025(1). doi:10.1155/jimr/5845167

BibTeX
@article{Zhang2025,
  author = {Zhang, Chenyun and Liu, Haizhou},
  title = {Advancements and Future Directions of Dual‐Target Chimeric Antigen Receptor T‐Cell Therapy in Preclinical and Clinical Studies},
  journal = {Journal of Immunology Research},
  year = {2025},
  volume = {2025},
  number = {1},
  doi = {10.1155/jimr/5845167}
}
Kostenlos starten →